David Samadi: Prostate Cancer Mostly Affects Older Men

Cancer is a very complicated disease. Once it is found in the body of a human being, treatment has to be started fast before it can spread and become fatal to the patient. Diagnosing the medical condition, however, is not a walk in the park. Some patients might not experience any symptoms, making it a silent killer. When most people are discovering the medical condition, it is already spread to other parts of the body. The medical condition is common among all people, regardless of their age, religion, gender or race. Individuals who are older are at a higher risk of getting the dangerous disease. Some young people are also battling the dangerous disease in the modern times.

In the United States, millions of people are living with cancer. Some of these individuals have top positions in the government while others are respected figures holding great offices. Cancer does not spare anyone. Mitt Romney is one of the latest cancer victims in the country. The former Republican presidential candidate realized that he had a tumor that was growing. The tumor made him lack sleep on several occasions because he knew that it could be cancerous. After undergoing surgery, the doctors realized that the cancer was in the initial stages, and it could be cured. The politician got treatment in one of the leading medical facilities in the country, and this is how his life was saved. The businessman is almost seventy years old.

Mitt Romney is one of the many seniors who have had to deal with cancer in their life time. Prostate cancer affects men who are older, and it is very rare in men who are in their forties. The men who get a diagnosis in time can be cured without many difficulties. Medical practitioners say that this cancer has become the leading killer in men who are older in the recent times.

From HuffPo:  https://www.huffingtonpost.com/entry/dr-david-samadi-mitt-romneys-prostate-cancer-prognosis_us_5a5faa15e4b0549d1a953e94

David Samadi is a respected medical professional who is very passionate about getting rid of cancer in the international community. The doctor was trained in one of the leading universities in the entire world, and he is doing his best to ensure that people, especially men understand the disease. The businessman has conducted thousands of surgeries in his career, and he has made sure that his patients are declared cancer free at the end of the treatment. Samadi is currently based in the United States, and he travels in other parts of the world taking care of patients.

For More info: www.sharecare.com/doctor/dr-david-samadi-3

Thyroid Cancer May Go the Route of Polio

Some of the most devastating words somebody can hear are “you have cancer.” This news shocks even the strongest spirit. However, the internationally peer-reviewed journal, Oncotarget, knows that if your perspective on the situation is positive, you are much more likely to be able to defeat the plague of cancer. This is why they have dedicated themselves to evaluating various methods of cancer treatment and seeing how they affect one’s quality of life and satisfaction with their current state of affairs.

Oncotarget has been known to run articles showing how to improve both traditional therapies as well as therapies that are cutting edge. These constant evaluations have led to greatly influence worldwide.

Oncotarget recently ran an article on an interview they had with Dr. Carmelo Nucero. Dr. Carmelo Nucero is the world’s foremost leading expert on papillary thyroid carcinoma. Having been a doctor in practice for decades, he has seen the same unfortunate story played out again time after time. Those who had been suffering from papillary thyroid carcinoma see their carcinoma go into remission only to watch it explode throughout their body a few years later. At first, they are brave thinking they can use the same treatment. Unfortunately, at this stage, the cancer becomes drug-resistant and is incurable. Learn more about Oncotarget at researchgate.net

Dr. Carmelo Nucero wanted to spend his remaining years researching papillary thyroid carcinoma and how to make it stop resisting the drug vemurafenib. In his research, he discovered that vemurafenib was resisted because the body saw it as a foreign agent attacking the gene BRAF. Dr. Carmelo Nucero realized that if he can get the body to stop seeing vemurafenib as an attacking agent, he could be able to treat papillary thyroid carcinoma with greater effectiveness. Check the journal at SCImago Journal & Country Rank.

Dr. Carmelo Nucero was able to join hands with other doctors, and together their research showed that if vemurafenib and palbociclib were used in treatment, the body would stop seeing vemurafenib as a foreign agent needing to be eliminated.

Listen: https://soundcloud.com/oncotarget

For more cutting-edge holistic strategies listen to Oncotarget’s podcast free on iTunes.

Clay Seagull; the Man Leading Seattle Genetic Towards Prosperity

Clay Seagull describes life in a funny way. According to a recent interview, he did with ideamensch; Clay describes how he saw things at different stages in his life. During his twenties, he thought he knew everything, during his thirties, he realized that there was much he was yet to learn, now in his forties, Clay says that he has finally confirmed that he doesn’t know much. Clay B. Seagull, the man who co-founded Seattle Genetics back in the year 1998, has achieved so much in his life. He is both the Chief Executive Officer and president of Seattle. Besides this, he is also the chairman of the company’s board.

Clay is a trained scientist whose training is centered on cancer therapies. His love for science was what drove him to create Seattle Genetics, which deals with the provision of various treatment services. During that time, he yearned to create a platform where it would be possible to carry out rigorous and effective research and still be in a position to create effective drugs from the research. All these things would, in turn, achieve one thing which was to help patients from different backgrounds find a cure for the different diseases that they were suffering from.

Since the founding of the company, Siegall has been guiding Seattle from the frontline over the years. Today, Seattle is among the top companies when it comes to the development of antibody-drug conjugates, which are commonly referred to as ADCs. In 2011, the company received FDA approval for their first antibody-drug conjugate product, which they called ADCETRIS. Since the approval, Seattle has been working with Takeda Pharmaceutical Company to advertise and sell the drug. ADCETRIS is now enjoying a global market. It has been approved and is being sold in 65 countries at the moment.

Before Siegall thought of creating Seattle Genetics, he worked at the Bristol-Myers Squibb Pharmaceutical Research Institute. He worked here between 1991 and 1997. He also worked at the National Institute of Health and at the National Cancer Institute after that. Dr. Siegall targets to achieve an effective and efficient cure for cancer through his organization, and one can tell that it is achievable through the stride that he has made in the past.

Eric Lefkofsky Powerfully Understated

In 2013 Eric and Liz Lefkofsky, the Chicago-based husband and wife philanthropic team
pledged to give away half of their fortune. Some might take one look at this mild-mannered wiry man with salt and pepper hair and question the validity of the offer. Don’t get it twisted, he can back it up, and if you live in Chicago you could very well receive it. Eric Lefkofsky is a man of immense wealth. Forbes has estimated his worth at $750 million. That fact alone catches the attention of everyone when his name or foundation is mentioned. Eric Lefkofsky and his wife take seriously the duty of giving back to the community. He is one of the world’s wealthiest entrepreneurs, and he and his wife are dedicated to civic and humanitarian causes especially when they involve their hometown of Chicago.

Born in Detriot, Michigan in 1969, Lefkofsky is the son of an engineer and school teacher. He graduated with honors from the University of Michigan, and he received his Juris Doctor from the University of Michigan Law School. Lefkofsky began his career very humbly selling carpet. After law school, he and a friend borrowed enough money from relatives to buy a clothing company. From there his career took a meteoric climb that has ultimately led him to successfully found over seven entrepreneurial ventures. StarBelly, one of his first ventures, made tools for building websites. He sold his interest in that company in 2000 for $240 million. Two other ventures, Inner Workings and Echo Global Logistics have gone public. Inner Workings provides printing capabilities over the web, while Echo Global Logistics is a transportation and logistics outsourcing business.

Eric Lefkofsky believes in the power technology and the internet to update an industry and keep it on the cutting edge. His book Accelerated Disruption talks about utilizing this power. “Disruptive businesses are born everyday,” he says in the book. What is a disruptive business? One that has a great idea that offers better choices, better prices, more convenience, and could possibly remake an industry. The business, however, fails, because the owner didn’t factor into his plan how technology’s fast pace can create a rival over night. The book essentially is about developing your business while keeping an eye on the fast pace of technological advances.

Lefkofsky’s objective is to take and use technology in any concern that affects mankind. That concept is most interestingly applied to his work with Tempus. Tempus is a company that has built operating systems used to fight cancer. The goal is to use data and machines as learning tools that will harness and analyze analytical and therapeutic data so that physicians will be empowered and able to make real time decisions about patient care.

Follow Lefkofsky on Facebook to stay up-to-date.